Clinical Trials Browser

Interventional × Triple Negative Breast Neoplasms × Sorafenib × Clear all

NCT02624700 2020-07-14

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

13 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms